Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women.

We evaluated associations between reproductive and lifestyle risk factors with breast cancer tumor marker status in a case-control study. Cases were premenopausal women living in Vietnam and China who were eligible for a clinical trial of oophorectomy and tamoxifen as treatment for breast cancer (n = 682). Controls were nonrelative hospital visitors, matched on age to the cases (n = 649). Immunohistochemical analysis was used to identify the presence of estrogen receptor (ER) and progesterone receptor and the overexpression of HER-2/neu oncogene. Odds ratios (OR) and 95% confidence intervals (95% CI) were estimated using unconditional logistic regression, adjusted for known confounders. Overall, 280 (61%) tumor samples were ER positive and 176 (38%) were ER negative. HER-2/neu overexpression was detected in 161 (35%) samples, whereas 286 (26%) samples were HER-2/neu negative. We observed an inverse trend between increasing parity and decreasing breast cancer risk (P = 0.002). Women ages > or =25 years at first birth had increased breast cancer risk compared with women ages <25 years at first birth (OR, 1.53; 95% CI, 1.20-1.95). Women who consumed alcohol had increased risk of breast cancer compared with women who did not (OR,1.85; 95% CI, 1.32-2.61). Compared with controls, OR estimates for breast cancer by parity and age at first birth were significantly associated with ER and/or HER-2/neu tumor status by Wald test (P < 0.05). Family history, age at menarche, cumulative lactation, body mass index, and education were not significantly related to breast cancer risk. Our findings support the hypothesis that some breast cancer risk factors differ by ER and HER-2/neu tumor marker subtypes.

[1]  I. Bleiweiss,et al.  Proliferative indices and oncoprotein expression in benign and malignant breast biopsies , 1995, Annals of Surgical Oncology.

[2]  Graham A Colditz,et al.  Risk factors for breast cancer according to estrogen and progesterone receptor status. , 2004, Journal of the National Cancer Institute.

[3]  J. Potter,et al.  The shape of age–incidence curves of female breast cancer by hormone-receptor status , 1999, Cancer Causes & Control.

[4]  D. Parkin,et al.  Time trends in cancer mortality in China: 1987–1999 , 2003, International journal of cancer.

[5]  F. Berrino,et al.  Role of hormonal risk factors in HER2-positive breast carcinomas , 2003, British Journal of Cancer.

[6]  D. DeMets,et al.  Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Thomas,et al.  Breast cancer in relation to induced abortions in a cohort of Chinese women , 2002, British Journal of Cancer.

[8]  Janet E Olson,et al.  Interaction of dietary folate intake, alcohol, and risk of hormone receptor-defined breast cancer in a prospective study of postmenopausal women. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[9]  D. DeMets,et al.  Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Cerhan,et al.  Interaction of waist/hip ratio and family history on the risk of hormone receptor-defined breast cancer in a prospective study of postmenopausal women. , 2002, American journal of epidemiology.

[11]  S. Gapstur,et al.  Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms. , 2001, JAMA.

[12]  J. Ferlay,et al.  Globocan 2000 : cancer incidence, mortality and prevalence worldwide , 2001 .

[13]  N. Chatterjee,et al.  Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  T. Sellers,et al.  Association of menstrual and reproductive factors with breast cancer risk: Results from the Shanghai breast cancer study , 2000, International journal of cancer.

[15]  L. Bernstein,et al.  Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[16]  R C Millikan,et al.  Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. , 2000, American journal of epidemiology.

[17]  R. Millikan,et al.  Risk of breast cancer according to the status of HER-2/neu oncogene amplification. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[18]  M. Barbareschi,et al.  Prognostic value of estrogen receptor status can be improved by combined evaluation of p53, Bcl2 and PgR expression: an immunohistochemical study on breast carcinoma with long-term follow-up. , 1999, International journal of oncology.

[19]  C. Osborne,et al.  Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. J. van de Vijver,et al.  The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer. , 1999, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[21]  N. Sadick,et al.  Estrogen and progesterone receptors: their role in postsclerotherapy angiogenesis telangiectatic matting (TM). , 1999, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[22]  W. Thompson,et al.  Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[23]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Jacques Ferlay,et al.  Estimates of the worldwide incidence of 25 major cancers in 1990 , 1999, International journal of cancer.

[25]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[26]  M Dosemeci,et al.  Occupational risk factors for breast cancer among women in Shanghai. , 1998, American journal of industrial medicine.

[27]  J. Ross,et al.  The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy , 1998, Stem cells.

[28]  D. Parkin,et al.  Cancer incidence in Ho Chi Minh City, Viet Nam, 1995–1996 , 1998, International journal of cancer.

[29]  W. Willett,et al.  Risk factors for breast cancer in women with a breast cancer family history. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[30]  F. Berrino,et al.  Alcohol consumption and total estradiol in premenopausal women. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[31]  F. Speizer,et al.  Alcohol and breast cancer in women: a pooled analysis of cohort studies. , 1998, JAMA.

[32]  D. Allred,et al.  Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[33]  S. Martino,et al.  HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  W. Willett,et al.  Body size and risk of breast cancer. , 1997, American journal of epidemiology.

[35]  A. Bianco,et al.  c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  M. Sliwkowski,et al.  HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. , 1995, Oncogene.

[37]  J. Cerhan,et al.  Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there? , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[38]  A. Schindler,et al.  Level of c-erbB-2 oncoprotein in the homogenate of malignant and benign breast tumor samples. , 1995, European journal of gynaecological oncology.

[39]  P. Nasca,et al.  Alcohol consumption and breast cancer: estrogen receptor status and histology. , 1994, American journal of epidemiology.

[40]  P. Taylor,et al.  Effects of alcohol consumption on plasma and urinary hormone concentrations in premenopausal women. , 1993, Journal of the National Cancer Institute.

[41]  W. McGuire,et al.  Prognostic factors and therapeutic decisions in axillary node-negative breast cancer. , 1992, Annual review of medicine.

[42]  W. Willett,et al.  The Reliability of Self-Reported Alcohol Consumption in the Remote Past , 1992, Epidemiology.

[43]  W. McGuire,et al.  Prognostic factors and treatment decisions in axillary-node-negative breast cancer. , 1992, The New England journal of medicine.

[44]  B. Ljung,et al.  The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. , 1992, Oncogene.

[45]  A. Hart,et al.  Differences in breast cancer risk factors to neu (c-erbB-2) protein overexpression of the breast tumor. , 1992, Cancer research.

[46]  D. DeMets,et al.  Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. , 1991, Annals of internal medicine.

[47]  M. Fernö,et al.  Her-2/neu and INT2 proto-oncogene amplification in malignant breast tumors in relation to reproductive factors and exposure to exogenous hormones. , 1991, Journal of the National Cancer Institute.

[48]  Z. Rayter,et al.  Steroid receptors in breast cancer , 1991, British Journal of Surgery.

[49]  M. J. van de Vijver,et al.  The molecular biology of breast cancer. , 1991, Biochimica et biophysica acta.

[50]  B. Henderson,et al.  Risk factors for breast cancer in Chinese women in Shanghai. , 1988, Cancer research.

[51]  B. Henderson,et al.  Risk factors for breast cancer in Tianjin, People's Republic of China. , 1985, National Cancer Institute monograph.

[52]  G. Greene,et al.  Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells , 1984, Nature.

[53]  J. Wittliff Steroid‐hormone receptors in breast cancer , 1984, Cancer.

[54]  Ketcham As,et al.  Risk factors in breast cancer. , 1975 .

[55]  C. D. HAAGENSEN,et al.  Diseases of the Breast , 1972 .